Derived from the pioneer GSK-J1, GSK-J4 is a cell-permeable UTX and JMJD3 blocker capable of affecting cell growth and survival especially in glioma and leukemia cells, where the H3K27me dysregulation occurs recurrently [156,157,158]. The gene discussed is KDM6B; the disease is leukemia.